ArticleWorld journal of gastroenterology2018
Optimal immunosuppressor induces stable gut microbiota after liver transplantation.
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 47 citations in OpenAlex.
- Synergies and Trade-Offs in Modern Poultry Nutrition: An Integrated Framework Linking Animal Health, Productivity and Greenhouse Gas Mitigation.Veterinary sciences · 2026Review
- Effects of tacrolimus treatment on the gut microbiota and metabolites in liver transplant recipients.PloS one · 2026Article
- Rapamycin immunomodulation utilizes time-dependent alterations of lymph node architecture, leukocyte trafficking, and gut microbiome.JCI insight · 2025Article
- The gut microbiota in liver transplantation recipients during the perioperative and postoperative recovery period.Frontiers in microbiology · 2025Article
- Influence of the gut microbiota on the pharmacokinetics of tacrolimus in liver transplant recipients: insights from microbiome analysis.Frontiers in microbiology · 2025Article
- Gut Microbial Dysbiosis and Implications in Solid Organ Transplantation.Biomedicines · 2024Review
- Review
- Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.BMC nephrology · 2024Review
- Update on the reciprocal interference between immunosuppressive therapy and gut microbiota after kidney transplantation.World journal of transplantation · 2024Review
- Updated Insights into Probiotics and Hepatobiliary Diseases.Biomedicines · 2024Review
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- Review
- Association between salivary microbiota and renal function in renal transplant patients during the perioperative period.Frontiers in microbiology · 2023Article
- Gut microbiota dynamics in a 1-year follow-up after adult liver transplantation in Northeast China.Frontiers in physiology · 2023Article
- Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease.Frontiers in microbiology · 2023Review
- Combination ofFrontiers in cellular and infection microbiology · 2023Article
- ABO-Incompatible Liver Transplantation under the Desensitization Protocol with Rituximab: Effect on Biliary Microbiota and Metabolites.Journal of clinical medicine · 2022Article
- Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.International journal of molecular sciences · 2022Review
- IL-18BP Improves Early Graft Function and Survival in Lewis-Brown Norway Rat Orthotopic Liver Transplantation Model.Biomolecules · 2022Article
- [How I treat gastrointestinal tract acute graft versus host disease with fecal microbiota transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the influence of different doses of tacrolimus (FK506) on gut microbiota after liver transplantation (LT) in rats.
methodsSpecific pathogen-free Brown Norway (BN) rats and Lewis rats were separated into five groups: (1) Tolerance group (BN-BN LT,
resultsCompared to the FK506-H and FK506-L groups, FK506-M was optimal for maintaining immunosuppression and inducing normal graft function; the FK506-M maintained gut barrier integrity and low plasma endotoxin levels; furthermore, DGGE results showed that FK506-M induced stable gut microbiota. Diversity analysis indicated that FK506-M increased species richness and rare species abundance, and cluster analysis confirmed the stable gut microbiota induced by FK506-M. Phylogenetic tree analysis identified crucial bacteria associated with FK506-M; seven of the nine bacteria that were decreased corresponded to
conclusionCompared to the low or high dosage of FK506, an optimal dosage of FK506 induced immunosuppression, normal graft function and stable gut microbiota following LT in rats. The stable gut microbiota presented increased probiotics and decreased potential pathogenic endotoxin-producing bacteria. These findings provide a novel strategy based on gut microbiota for immunosuppressive dosage assessment for recipients following LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.